Glaxo Withdraws Raxar Following Seven Fatal Cardiovascular AEs
Executive Summary
Glaxo Wellcome is withdrawing the quinolone antibiotic Raxar (grepafloxacin) from the worldwide markets after receiving a total of seven reports of cardiovascular event-related fatalities associated with use of the drug.
You may also be interested in...
GSK/Otsuka settle Raxar dispute
GlaxoSmithKline agrees to make payment to Otsuka to settle the companies' dispute over 1999 withdrawal of the antibiotic Raxar. Otsuka initiated arbitration proceedings in December 2001, arguing that the withdrawal constituted material breach of contract. Glaxo withdrew Raxar due to cardiovascular safety concerns (1"The Pink Sheet" Nov. 1, 1999, p. 17)...
GSK/Otsuka settle Raxar dispute
GlaxoSmithKline agrees to make payment to Otsuka to settle the companies' dispute over 1999 withdrawal of the antibiotic Raxar. Otsuka initiated arbitration proceedings in December 2001, arguing that the withdrawal constituted material breach of contract. Glaxo withdrew Raxar due to cardiovascular safety concerns (1"The Pink Sheet" Nov. 1, 1999, p. 17)...
Bayer Avelox Skin Infection Indication "Approvable"; Needs More Safety Data
Bayer's Avelox (moxifloxacin) is "approvable" for the treatment of uncomplicated skin and skin structure infections, FDA said in a Dec. 10 letter granting the antibiotic approval for three other indications.